InsiderTrades.com logo
Wagner M. Zago net worth and biography
  • Phone
  • Email
  • Website

Wagner Zago Biography and Net Worth

Insider of Prothena
Dr. Zago has served as our Chief Scientific Officer since 2017.  He joined Prothena in 2012 when the company was founded, first as Head of Pharmacology and Neuropathology and more recently as Vice President, Head of Research. Between 2006 and 2012, Dr. Zago was Principal Scientist at Elan Pharmaceuticals, Inc., performing research aimed at developing new therapeutics for CNS disorders, including beta amyloid-targeted therapies and supportive research for the development of natalizumab, which was commercialized by Biogen for relapsing multiple sclerosis. While in this position, between 2009 and 2013, he also served as a Scientist at Janssen Alzheimer Immunotherapy, where he made significant discoveries about vascular changes associated with anti-beta amyloid immunotherapy. Dr. Zago earned his BS in Biomedicine from the Universidade Federal de Sao Paulo (Escola Paulista de Medicina), Brazil, and his M.S. and Ph.D. in Pharmacology at the Universidade de Sao Paulo, Brazil, and was a Post-Doctoral Researcher at the University of California – San Diego and the Burnham Institute.

What is Wagner M. Zago's net worth?

The estimated net worth of Wagner M. Zago is at least $157.50 thousand as of June 22nd, 2021. Dr. Zago owns 15,000 shares of Prothena stock worth more than $157,500 as of April 10th. This net worth evaluation does not reflect any other assets that Dr. Zago may own. Learn More about Wagner M. Zago's net worth.

How do I contact Wagner M. Zago?

The corporate mailing address for Dr. Zago and other Prothena executives is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. Prothena can also be reached via phone at (531) 236-2500 and via email at [email protected]. Learn More on Wagner M. Zago's contact information.

Has Wagner M. Zago been buying or selling shares of Prothena?

Wagner M. Zago has not been actively trading shares of Prothena during the past quarter. Most recently, Wagner M. Zago sold 4,000 shares of the business's stock in a transaction on Wednesday, August 2nd. The shares were sold at an average price of $67.05, for a transaction totalling $268,200.00. Learn More on Wagner M. Zago's trading history.

Who are Prothena's active insiders?

Prothena's insider roster includes Christopher Henney (Director), Carol Karp (Insider), Gene Kinney (Pres), Michael Malecek (Insider), Tran Nguyen (CFO & Chief Strategy Officer ), Dennis Selkoe (Director), Brandon Smith (COO), Karin Walker (CAO), and Wagner Zago (Insider). Learn More on Prothena's active insiders.

Wagner M. Zago Insider Trading History at Prothena

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/2/2023Sell4,000$67.05$268,200.00View SEC Filing Icon  
6/7/2023Sell19,000$71.06$1,350,140.00View SEC Filing Icon  
6/22/2021Sell115,250$46.15$5,318,787.5015,000View SEC Filing Icon  
2/18/2021Sell7,540$25.50$192,270.007,540View SEC Filing Icon  
See Full Table

Wagner M. Zago Buying and Selling Activity at Prothena

This chart shows Wagner M Zago's buying and selling at Prothena by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Prothena Company Overview

Prothena logo
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.
Read More

Today's Range

Now: $10.50
Low: $10.37
High: $10.60

50 Day Range

MA: $9.27
Low: $8.35
High: $10.65

2 Week Range

Now: $10.50
Low: $4.32
High: $11.69

Volume

319,030 shs

Average Volume

533,531 shs

Market Capitalization

$565.22 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A